Korelasi Antara Kadar Ferritin Serum dengan Procalcitonin Pada Pasien COVID-19

Mita Puspita Sari; Rizana Fajrunni’mah; Dewi Astuti; Kunti Wijiarti; Farida Murtiani

doi:10.32667/ijid.v8i2.151

Korelasi Antara Kadar Ferritin Serum dengan Procalcitonin Pada Pasien COVID-19

Mita Puspita Sari, Rizana Fajrunni’mah, Dewi Astuti, Kunti Wijiarti, Farida Murtiani

Abstract

Latar Belakang: Wabah Coronavirus Disease 2019 (COVID-19) disebabkan oleh Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Temuan laboratorium pada pasien COVID-19 yang parah melibatkan penanda inflamasi yang meningkat, termasuk feritin. Feritin adalah mediator kunci dari disregulasi imun, terutama di bawah hiperferitinemia ekstrim. Pasien COVID-19 dengan hiperferitinemia memiliki tingkat penanda inflamasi yang jauh lebih tinggi, salah satunya adalah prokalsitonin (PCT). Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan kadar feritin serum dengan PCT pada pasien COVID-19. Metode: Metode penelitian ini adalah analitik korelatif. Sampel adalah data rekam medik sebanyak 463 pasien COVID-19 di RS Persahabatan periode Januari – Desember 2021. Hubungan antara kadar feritin serum dengan kadar PCT dianalisis secara statistik menggunakan uji Spearman. Hasil: Hasil penelitian ini diperoleh 240 (51,8%) pasien laki-laki dengan kelompok umur tertinggi 46-59 tahun sebanyak 160 (34,6%) pasien dan 60 tahun sebanyak 163 (35,0%) pasien. Rerata kadar feritin serum adalah 995.218 µg/L dengan kadar minimum 11,3 µg/L dan kadar maksimum 22.612,7 µg/L, sedangkan rerata kadar PCT adalah 0,3892 ng/mL dengan kadar minimum 0 ,00 ng/mL dan kadar maksimum 50,73 ng/mL. Hasil uji korelasi Spearman diperoleh nilai p 0,000 dan rho 0,573. Kesimpulan: Rumah sakit atau institusi pelayanan dapat menerapkan hasil penelitian ini dengan melakukan salah satu pemeriksaan kadar feritin serum atau PCT sambil memantau co-diagnosis pasien.

Keywords

Coronavirus Disease 2019 (COVID-19), Ferritin serum, Procalcitonin (PCT)

Full Text:

PDF

References

Pangestu N. Pemeriksaan Laboratorium pada Coronavirus Disease 2019 ( COVID-19 ). 2020;7:304–19.

Velavan TP, Meyer CG. The COVID-19 epidemic. 2020;25(3):278–80.

Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol. 2021;242.

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;1446.

WHO. Situation Report: World Health Organization. Coronavirus Dis 2019. 2022;87(February):11.

Styawan DA. Pandemi Covid-19 Dalam Perspektif Demografi. In: Seminar Nasional Official Statistics. 2020. p. 182–9.

Cortis D. On determining the age distribution of COVID-19 pandemic. Front public Heal. 2020;8:202.

Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–11.

Guo T, Shen Q, Guo W, He W, Li J, Zhang Y, et al. Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province , China : A Multicenter , Retrospective Study. 2020;410011(139):467–75.

Kyriazis M, Mikellides G, Pantelidakis H, Polycarpou M, Panayiotou B. COVID-19 Isolation and Risk of Death in Cyprus Elderly People. Front Med. 2021;1263.

Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):1–8.

Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur Respir J. 2020;56(3).

Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.

Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Heal. 2021;8:582932.

Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131–4.

Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.

Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–7.

Vargas M V, Rojo C C. Ferritin levels and COVID-19. Rev Panam Salud Publica/Pan Am J Public Heal. 2020;44:2019–20.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020;395(10229):1033–4. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30628-0

Kim YS, Son A, Kim J, Kwon S Bin, Kim MH, Kim P, et al. Chaperna-mediated assembly of ferritin-based middle East respiratory syndrome-coronavirus nanoparticles. Front Immunol. 2018;9(MAY):1–20.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

Gilbert DN. Neglected variables in the interpretation of serum procalcitonin levels in patients with septic shock. J Infect Dis. 2021;222(Suppl 2):S96–102.

Tang J, Lin J, Zhang E, Zhong M, Luo Y, Fu Y, et al. Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients. Medicine (Baltimore). 2021;100(22).

Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of IL-6, CRP, and PCT in patients with COVID-19. J Clin Virol. 2020;(January).

Boenisch S, Fae P, Drexel H, Walli AK, Fraunberger P. Are circulating levels of CRP compared to IL-6 and PCT still relevant in intensive care unit patients? 1. Laboratoriumsmedizin. 2013;37(1).

Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect. 2020;81(4):647–79.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.

Li L quan, Huang T, Wang Y qing, Wang Z ping, Liang Y, Huang T bi, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–83.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

Cen Y, Chen X, Shen Y, Zhang X, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019da multi-centre observational study. 2020;(January).

Sarvasti D. Pengaruh Gender Dan Manifestasi Kardiovaskular Pada COVID-19. Indones J Cardiol. 2020;41(2):126–32.

De Groot NG, Bontrop RE. COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males? Springer; 2020.

Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8(4):e20.

Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;(January).

Antezana JPE, Ferrufino NFL, Alanoca AM, Alarcón-de-la-vega G, Arnez LEA, Saavedra MAB, et al. Risk factors for mortality in patients with Coronavirus Disease 2019 ( COVID-19 ) in Bolivia : An analysis of the first 107 confirmed cases. 2020;2019:238–42.

Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020;(January).

Kang S-J, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154.

Vermonte P, Wicaksono TY. Karakteristik dan Persebaran COVID-19 di Indonesia : Temuan Awal. CSIS Comment DMRU-043-ID. 2020;(April):1–12.

Yağcı S, Serin E, Acicbe Ö, Zeren Mİ, Odabaşı MS. The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID‐19. Int J Lab Hematol. 2021;43:142–51.

Jia F, Liu H, Kang S. NCOA4-Mediated Ferritinophagy: A Vicious Culprit in COVID-19 Pathogenesis? Front Mol Biosci. 2021;8:761793.

Singer AJ, Morley EJ, Meyers K, Fernandes R, Rowe AL, Viccellio P, et al. Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation. Ann Emerg Med. 2020;76(4):394–404.

Fernandez FH, Valencia HS, Aponte RAB, Jimenez RC, Martin OA, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: Neuroimaging, histological and clinical description. Brain. 2020;143(10):3089–103.

Taneri PE, Ochoa SAG, Llanaj E, Raguindin PF, Rojas LZ, Díaz ZMR, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–73.

Rosário C, Goddard GZ, Holtz EGM, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11(1).

Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia. Lab Investig. 2020;100(6):794–800.

Keski H. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. Indian J Hematol Blood Transfus [Internet]. 2021;37(4):534–42. Available from: https://doi.org/10.1007/s12288-021-01407-y

Shen Y, Cheng C, Zheng X, Jin Y, Duan G, Chen M, et al. Elevated procalcitonin is positively associated with the severity of COVID-19: A meta-analysis based on 10 cohort studies. Medicina (B Aires). 2021;57(6):594.

Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci. 2022;59(1):54–65.

Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J intensive care. 2017;5(1):1–7.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states : A clinical − therapeutic staging proposal. 2020;(Figure 1):3–5.

DOI: https://doi.org/10.32667/ijid.v8i2.151